Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration

Therapeutic Drug Monitoring

Volumn 30, Issue 4, 2008, Pages 456-461

  Langers, Pieter ^a   Press, Rogier R ^a   Hartigh, Jan Den ^a   Cremers, Serge C L M ^a   Baranski, Andrzej G ^b   Lamers, Cornelis B H W ^a   Hommes, Daan W ^a   Hoek, Bart Van ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Limited sampling model; Liver transplantation; Tacrolimus; Therapeutic drugmonitoring

Indexed keywords

TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; HUMAN; HUMAN TISSUE; LIVER TRANSPLANTATION; MALE; MATHEMATICAL MODEL; MORNING DOSAGE; MULTIPLE REGRESSION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; VALIDATION STUDY; BLOOD; EPIDEMIOLOGY; IMMUNOLOGY; MIDDLE AGED; POPULATION; REGRESSION ANALYSIS; STATISTICAL MODEL;

ADULT; AGED; AREA UNDER CURVE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, STATISTICAL; POPULATION; REGRESSION ANALYSIS; SAMPLING STUDIES; TACROLIMUS; YOUNG ADULT;

EID: 58149128142     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31818162b9     Document Type: Article

References (31)

1. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62:920-926.
2. Venkataramanan R, Shaw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001;41:542-551.
3. Levy GA. C2 monitoring strategy for optimizing cyclosporine immunosuppression from the Neoral formulation. BioDrugs. 2001;15:279-290.
4. Nashan B, Cole E, Levy G, et al. Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation. 2002;73:S3-11.
5. Morton JM, Aboyoun CL, Malouf MA, et al. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation. J Heart Lung Transplant. 2004;23:1035-1039.
6. Cole E, Midtvedt K, Johnston A, et al. Recommendations for the implementation of Neoral C(2) monitoring in clinical practice. Transplantation. 2002;73:S19-S22.
7. Cantarovich M, Barkun JS, Tchervenkov JI, et al. Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation. 1998;66:1621-1627.
8. Grant D, Kneteman N, Tchervenkov J, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation. 1999;67:1133-1137.
9. Lake JR. Benefits of cyclosporine microemulsion (Neoral) C(2) monitoring are sustained at 1 year in de novo liver transplant recipients. Transplant Proc. 2001;33:3092-3093.
10. Dunn S, Falkenstein K, Cooney G. Neoral C(2) monitoring in pediatric liver transplant recipients. Transplant Proc. 2001;33:3094-3095.
11. Barakat O, Peaston R, Rai R, et al. Clinical benefit of monitoring cyclosporine C2 and C4 in long-term liver transplant recipients. Transplant Proc. 2002;34:1535-1537.
12. Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr postdose levels (C2). Transplantation. 2002;73:953-959.
13. Langers P, Cremers SC, den Hartigh J, et al. Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients. Liver Transpl. 2004;10:183-189.
14. Macchi-Andanson M, Charpiat B, Jelliffe RW, et al. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit. 2001;23:129-133.
15. Mardigyan V, Tchervenkov J, Metrakos P, et al. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation. Clin Ther. 2005;27:463-469.
16. Dansirikul C, Staatz CE, Duffull SB, et al. Sampling times for monitoring tacrolimus in stable adult liver transplant recipients. Ther Drug Monit. 2004;26:593-599.
17. Scholten EM, Cremers SCLM, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant patients. Kidney Int. 2005;67:2440-2447.
18. Langers P, Cremers SC, den Hartigh J, et al. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation. Aliment Pharmacol Ther. 2005;21:549-557.
19. Langers P, Cremers SC, den Hartigh J, et al. Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice. Aliment Pharmacol Ther. 2007;26:1447-1456.
20. Busuttil RW, Klintmalm GB, Lake JR, et al. General guidelines for the use of tacrolimus in adult liver transplant patients. Transplantation. 1996;61: 845-847.
21. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002;62:1481-1502.
22. Proost JH. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Int J Clin Pharmacol Ther. 1995; 33:531-536.
23. Rowland M, Tozer TN. Clinical Pharmacokinetics, Concepts and Applications. Philadelphia: Lee & Febiger; 1989.
24. Armendariz Y, Pou L, Cantarell C, et al. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit. 2005 7:431-434.
25. Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals. Clin Pharmacokinet. 1998;34:57-77.
26. Moller A, Iwasaki K, Kawamura A, et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos. 1999;27:633-636.
27. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
28. Sgrosso JL, Araujo GL, Vázquez MC. Tacrolimus pharmacokinetics in heart transplant. Transplant Proc. 2002;34:142-143.
29. Armendáriz Y, Pou L, Cantarell C, et al. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit. 2005;27:431-434.
30. Cantarovich M, Fridell J, Barkun J, et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. Transplant Proc. 1998;30:1460-1461.
31. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43: 623-653.